Corvus 制药 CRVS
$10.54 +$0.81 (+8.32%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $10.60 +0.57%
开盘$10.65
昨收$9.73
当日区间$9.64 – $10.96
成交量1.26M
市值$889.08M
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例86.6%-1.44 个百分点，较上季度
持仓机构数207-1 ，较上季度
内部人近期交易47次买入 / 2次卖出净买入
空头持仓比例21.36% 占流通股回补天数 14.9 · 截至 15 Oct 2026
卖空成交量占比21.2%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：−$145.2K（7个净流入日，13个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有31.4%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从21.77%降至21.36%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +152,628 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +978,389 | 8.5% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +908,099 | 5.3% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +871,826 | 4.5% |
| Eversept Partners, L.P. | Hedge Fund | 2026/Q3 | +747,994 | 0.9% |
| Bank of America Corporation | Public Company | 2026/Q3 | +520,794 | 0.9% |
| Wellington Management Group | Mutual Fund | 2026/Q3 | +413,115 | 3.2% |
| Perceptive Advisors LLC | VC/PE Fund | 2026/Q3 | +375,000 | 3.2% |
| Braidwell LP | Hedge Fund | 2026/Q3 | +373,500 | 2.5% |
| Trexquant Investment LP | Hedge Fund | 2026/Q3 | +296,347 | 0.4% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q3 | +245,339 | 0.9% |
| Hood River Capital Management LLC | Mutual Fund | 2026/Q3 | +236,696 | 1.9% |
| Catalio Capital Management, LP | VC/PE Fund | 2026/Q3 | +188,955 | 1.3% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +181,623 | 1.2% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +175,255 | 0.6% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 10 Jun 2026 | Richard van den Broek | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Ian T. Clark | Former Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | David Moore | Independent Director | Open Market Acquisition | +21,700 | $11.53 | 21,700 |
| 10 Jun 2026 | David Moore | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 17 May 2026 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Open Market Acquisition | +6,932 | $12.05 | 2,331,742 |
| 27 Jan 2026 | Peter Thompson | Co-Founder & Independent Director | Derivative Exercise and Retained | +210,000 | $15.00 | 210,000 |
| 3 Dec 2025 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Other Derivative Acquisition | +1,000,000 | $8.81 | 1,000,000 |
| 3 Dec 2025 | Leiv Lea | Chief Financial Officer | Other Derivative Acquisition | +400,000 | $8.81 | 400,000 |
| 3 Dec 2025 | Jeffrey Arcara | Senior VP & Chief Business Officer | Other Derivative Acquisition | +100,000 | $8.81 | 100,000 |
| 3 Dec 2025 | William Jones | Senior Vice President of Pharmaceutical Development | Other Derivative Acquisition | +400,000 | $8.81 | 400,000 |
| 1 Oct 2025 | David Moore | Independent Director | Other Derivative Acquisition | +30,000 | $7.04 | 30,000 |
| 26 Jun 2025 | OrbiMed Advisors LLC | Derivative Exercise and Sale | -1,176,332 | $4.16 | 7,165,006 | |
| 26 Jun 2025 | OrbiMed Advisors LLC | Derivative Exercise and Retained | +221,352 | $3.50 | 7,165,006 | |
| 11 Jun 2025 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Ian T. Clark | Former Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Scott William Morrison | Former Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 3 Jun 2025 | William Jones | Senior Vice President of Pharmaceutical Development | Derivative Exercise and Retained | +19,357 | $3.50 | 173,130 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 17,967,756 | 21.4% | 14.9 |
| 30 Sep 2026 | 17,797,751 | 21.2% | 13.3 |
| 15 Sep 2026 | 17,180,341 | 20.4% | 18.2 |
| 31 Aug 2026 | 19,017,840 | 22.6% | 29.6 |
| 14 Aug 2026 | 19,127,098 | 22.7% | 22.5 |
| 31 Jul 2026 | 18,310,256 | 21.8% | 22.5 |
暂无评论——快来第一个聊聊 CRVS。
登录后参与讨论。